Literature DB >> 32606208

Global burden of oesophageal and gastric cancer by histology and subsite in 2018.

Melina Arnold1, Jacques Ferlay2, Mark I van Berge Henegouwen3, Isabelle Soerjomataram2.   

Abstract

OBJECTIVES: To provide updated estimates of the global burden of oesophageal and gastric cancer by subsite and type.
METHODS: Using data from population-based cancer registries, proportions of oesophageal adenocarcinoma (OAC) and squamous cell carcinoma (OSCC) out of all oesophageal as well as cardia gastric cancer (CGC) and non-CGC (NCGC) out of all gastric cancer cases were computed by country, sex and age group. Proportions were subsequently applied to the estimated numbers of oesophageal and gastric cancer cases from GLOBOCAN 2018. Age-standardised incidence rates (ASR) were calculated.
RESULTS: In 2018, there were an estimated 572 000 new cases of oesophageal cancer worldwide, 85 000 OACs (ASR 0.9 per 100 000, both sexes combined) and 482 000 OSCCs (ASR 5.3). Out of 1.03 million gastric cancers, there were an estimated 181 000 cases of CGC (ASR 2.0) and 853 000 cases of NCGC (ASR 9.2). While the highest incidence rates of OSCC, CGC and NCGC were observed in Eastern Asia (ASRs 11.1, 4.4 and 17.9, respectively), rates of OAC were highest in Northern Europe (ASR 3.5). While globally OSCC and NCGC remain the most common types of oesophageal and gastric cancer, respectively, rates of OAC exceed those of OSCC in an increasing number of high-income countries.
CONCLUSIONS: These updated estimates of the global burden of oesophageal and gastric cancer by subtype and site suggest an ongoing transition in epidemiological patterns. This work will serve as a cornerstone for policy-making and will aid in developing appropriate cancer control strategies. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer prevention; epidemiology; gastric cancer; histopathology; oesophageal cancer

Mesh:

Year:  2020        PMID: 32606208     DOI: 10.1136/gutjnl-2020-321600

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  71 in total

Review 1.  [Reconstruction following gastrectomy].

Authors:  Marie-Christin Weber; Maximilian Berlet; Alexander Novotny; Helmut Friess; Daniel Reim
Journal:  Chirurg       Date:  2021-01-26       Impact factor: 0.955

2.  Prevalence of lung tumors in patients with esophageal squamous cell carcinoma and vice versa: a systematic review and meta-analysis.

Authors:  Laurelle van Tilburg; Steffi E M van de Ven; Manon C W Spaander; Laurens A van Kleef; Robin Cornelissen; Marco J Bruno; Arjun D Koch
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

3.  METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.

Authors:  Huafu Li; Chunming Wang; Linxiang Lan; Leping Yan; Wuguo Li; Ian Evans; E Josue Ruiz; Qiao Su; Guangying Zhao; Wenhui Wu; Haiyong Zhang; Zhijun Zhou; Zhenran Hu; Wei Chen; Joaquim M Oliveira; Axel Behrens; Rui L Reis; Changhua Zhang
Journal:  Cell Mol Life Sci       Date:  2022-02-18       Impact factor: 9.261

4.  Urinary protein biomarker panel predicts esophageal squamous carcinoma from control cases and other tumors.

Authors:  Linlin Ji; Jianping Wang; Bo Yang; Jianping Zhu; Yini Wang; Jiaqi Jiao; Kai Zhu; Min Zhang; Liqiang Zhai; Tongqing Gong; Changqing Sun; Jun Qin; Guangshun Wang
Journal:  Esophagus       Date:  2022-07-06       Impact factor: 3.671

5.  Oesophageal and Gastric Cancer After Bariatric Surgery: an Up-to-Date Systematic Scoping Review of Literature of 324 Cases.

Authors:  Chetan Parmar; Sjaak Pouwels
Journal:  Obes Surg       Date:  2022-10-15       Impact factor: 3.479

6.  ML323, a USP1 inhibitor triggers cell cycle arrest, apoptosis and autophagy in esophageal squamous cell carcinoma cells.

Authors:  Yaxin Sun; Beibei Sha; Wenjing Huang; Miaomiao Li; Shan Zhao; Yuan Zhang; Jie Yan; Zheng Li; Jingwen Tang; Peiyan Duan; Jianxiang Shi; Pei Li; Tao Hu; Ping Chen
Journal:  Apoptosis       Date:  2022-06-02       Impact factor: 5.561

7.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Authors:  Yelena Y Janjigian; Kohei Shitara; Markus Moehler; Marcelo Garrido; Pamela Salman; Lin Shen; Lucjan Wyrwicz; Kensei Yamaguchi; Tomasz Skoczylas; Arinilda Campos Bragagnoli; Tianshu Liu; Michael Schenker; Patricio Yanez; Mustapha Tehfe; Ruben Kowalyszyn; Michalis V Karamouzis; Ricardo Bruges; Thomas Zander; Roberto Pazo-Cid; Erika Hitre; Kynan Feeney; James M Cleary; Valerie Poulart; Dana Cullen; Ming Lei; Hong Xiao; Kaoru Kondo; Mingshun Li; Jaffer A Ajani
Journal:  Lancet       Date:  2021-06-05       Impact factor: 79.321

8.  Comparison of short-term outcomes from the International Oesophago-Gastric Anastomosis Audit (OGAA), the Esophagectomy Complications Consensus Group (ECCG), and the Dutch Upper Gastrointestinal Cancer Audit (DUCA).

Authors: 
Journal:  BJS Open       Date:  2021-05-07

Review 9.  Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy.

Authors:  Melissa Schmidt; Richard J Hackett; Ann-Marie Baker; Stuart A C McDonald; Michael Quante; Trevor A Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-11-02       Impact factor: 46.802

10.  Comparison of short-term outcomes from the International Oesophago-Gastric Anastomosis Audit (OGAA), the Esophagectomy Complications Consensus Group (ECCG), and the Dutch Upper Gastrointestinal Cancer Audit (DUCA).

Authors: 
Journal:  BJS Open       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.